๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Wuhan
Clinical trial register · China

Clinical Trials in Wuhan

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 276 Beijing 6 Hangzhou 5 Wuhan 5 Qionghai 5
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai276 Beijing6 Hangzhou5 Wuhan5 Qionghai5
All 38 locations
Target enrolment
to
5 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
NCT07131150Idiopathic Pulmonary Fibrosis (IPF)
Ruijin Hospital
Phase 2
66
Beijing, Guangzhou, Shenzhen, Hebei, Zhengzhou, Wuhan, Changsha, Nanjing
2025-08-31
Recruiting
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases
NCT06747156Autoimmune Diseases
Ruijin Hospital
Phase EARLY_PHASE1
66
Wuhan, Nanjing, Shanghai
2024-12-23
Not yet open
Abnormal Glucose Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation
NCT06704542ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Diabetes Mellitus, Impaired Fasting Glucose
Ruijin Hospital
Observational
1,000
Zhengzhou, Wuhan, Shanghai, Hangzhou, Tianjin
2024-11
Active, closed
CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT
NCT06449586Hematologic Malignancy
Ruijin Hospital
Phase 3
250
Wuhan, Shanghai, Hangzhou
2024-07-01
Recruiting
Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
NCT06876688CNS Lymphoma
Ruijin Hospital
Phase 2
30
Beijing, Guangzhou, Henan, Shanghai, Wuhan
2023-11-30
Rows per page Showing 1–5 of 5
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-china/city/wuhan

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.